SCHEMBL4430839

SCHEMBL4430839

C[C@H](N)CNC(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
SLC1A3 P43003 1/20 0.54
SLC1A1 P43005 1/20 0.54
HTT P42858 1/20 0.54
CTSK P43235 3/20 0.52
CTSS P25774 3/20 0.52
CTSL P07711 2/20 0.52
SYK P43405 1/20 0.52
CTSB P07858 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
ATM Q13315 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PLAU P00749 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430842 1.00 LMNA (0.56) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL4431806 1.00 LMNA (0.56) LMNASMN1; SMN2SLC1A3SLC1A1HTT
Hydrochloric Acid SCHEMBL6534947 0.98 LMNA (0.55) LMNASMN1; SMN2SLC1A3SLC1A1HTT
Trifluoroacetic Acid SCHEMBL28688130 0.92 CTSS (0.53) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL27271973 0.87 SLC1A3 (0.52) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL13480436 0.87 SLC1A3 (0.52) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL5019077 0.87 LMNA (0.59) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL9293928 0.87 LMNA (0.59) LMNASMN1; SMN2HTTCTSKCTSS
SCHEMBL7471592 0.87 LMNA (0.56) LMNASMN1; SMN2SLC1A3SLC1A1HTT
SCHEMBL6216286 0.86 LMNA (0.58) LMNASMN1; SMN2HTTCTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3906225-A1 PANTOTHENAMIDE ANALOGUES MMV Medicines for Malaria Venture (CH) 2021-11-10 EP disclosed
WO-2020141155-A1 PANTOTHENAMIDE ANALOGUES MMV MEDICINES FOR MALARIA VENTURE (CH) 2020-07-09 WO disclosed
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed
WO-2002014324-A2 DIAZEPINONES AS ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 LMNA 4502/4885SMN1; SMN2 2612/4885SLC1A3 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.